Jasper Therapeutics, Inc. Appointed Herb Cross, as Corporate Secretary

On September 21, 2023, the Board of Directors of Jasper Therapeutics, Inc. (the ?Company?) appointed Herb Cross, age 51, as its Chief Financial Officer and Corporate Secretary. In this role, Mr. Cross is acting as the Company?s principal accounting officer and principal financial officer, effective upon the commencement of his employment with the Company, which was September 22, 2023. Prior to joining the Company, Mr. Cross had served as the Chief Financial Officer of Atreca, Inc., a biotechnology company, since February 2019.

From November 2017 to June 2018, he served as Chief Financial Officer of ARMO Biosciences, Inc., a biotechnology company. From February 2016 to November 2017, Mr. Cross served as Chief Financial Officer of Balance Therapeutics, Inc., a biotechnology company. From October 2013 to November 2015, he served as Chief Financial Officer of KaloBios Pharmaceuticals, Inc., a biotechnology company, and interim Chief Executive Officer from January 2015 to November 2015.

In December 2015, KaloBios filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code. KaloBios emerged from Chapter 11 in July 2016. From November 2010 to June 2013, Mr. Cross served as Chief Financial Officer of Affymax, Inc., a biotechnology company.

He served as a director of Apexigen, Inc. from July 2022 to August 2023 and Apexigen America, Inc. from October 2019 to August 2023. Mr. Cross received a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive). On September 21, 2023, in connection with the appointment of Mr. Cross as the Company?s Chief Financial Officer and Corporate Secretary and the Company?s principal financial officer and principal accounting officer, effective September 22, 2023, the Board approved the transition of Jeet Mahal, the Company?s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company?s Chief Operating Officer.

In connection with the transition, Mr. Mahal no longer serves as the Company?s Chief Financial Officer, Corporate Secretary, principal financial officer or principal accounting officer.